<DOC>
	<DOCNO>NCT00536861</DOCNO>
	<brief_summary>Lung cancer lead cause death worldwide . Brain metastases manifest first site disease failure 15-30 % patient non-small cell lung cancer ( NSCLC ) . The standard treatment patient multiple brain metastasis whole brain radiotherapy result modest survival 3-6 month . Drugs enhance effect cranial irradiation ( radiosensitizers ) may improve response rate . Erlotinib ( Tarceva ) oral agent register treatment patient metastatic NSCLC . Erlotinib show tumor activity patient present brain metastasis , preclinical study show may radiosensitizer . As prelude study investigate combination Erlotinib cranial radiotherapy , present study perform evaluate safety combine treatment .</brief_summary>
	<brief_title>Safety Study Radiotherapy Concurrent Erlotinib ( Tarceva® ) Brain Metastases From Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histological cytological confirmation nonsmall cell lung cancer ( NSCLC ) Diagnosis brain metastasis contrastenhanced CT scan Gadoliniumenhanced MRI Patients candidate surgery stereotactic radiosurgery RPA Class 1 2 ( Karnofsky performance status &gt; 70 ) Age &gt; 18 year No previous radiotherapy , surgery chemotherapy brain metastases Patients must able take oral medication . Patients unstable systemic disease except lung cancer ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , serious cardiac arrhythmia require medication , hepatic , renal metabolic disease ) . Granulocyte count &gt; 1.5 x 109/L platelet count &gt; 100 x 109/L OK Serum bilirubin must &lt; 1.5 upper limit normal ( ULN ) . AST and/or ALT &lt; 2 x ULN ( &lt; 5 x ULN clearly attributable liver metastasis ) Serum creatinine &lt; 1.5 ULN creatinine clearance &gt; 60 ml/min Patients reproductive potential must use effective contraception . For female childbearing potential negative pregnancy test must obtain within 72 hour start therapy . Able comply study followup procedure Written inform consent . Any unstable systemic disease ( include active infection , grade 4 hypertension , unstable angina , congestive heart failure , hepatic , renal metabolic disease ) . Signs , symptoms MRI finding consistent leptomeningeal metastasis . Concomitant use phenytoin anticonvulsant medication Prior therapy systemic antitumour therapy HER1/EGFR inhibitor ( small molecule monoclonal antibody therapy ) . Any malignancy precede 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer ) . Any significant ophthalmological abnormality , especially severe dry eye syndrome , keratoconjunctivitis sicca , Sjögren syndrome , severe exposure keratitis disorder likely increase risk corneal epithelial lesion . The use contact lenses recommend study . The decision continue wear contact lens discuss patient 's treat Oncologist ophthalmologist . Patients take oral medication , require intravenous alimentation , prior surgical procedure affect absorption , active peptic ulcer disease . Nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>erlotinib</keyword>
	<keyword>cranial radiotherapy</keyword>
</DOC>